SOURCE: AtheroGenics

July 17, 2007 11:34 ET

AtheroGenics to Report Second Quarter 2007 Financial Results on July 26, 2007

ATLANTA, GA--(Marketwire - July 17, 2007) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it will release its second quarter 2007 financial results on Thursday, July 26, 2007, before the U.S. financial markets open.

Conference Call and Webcast Information

Company officials will discuss second quarter results via conference call and webcast on Thursday, July 26, 2007, at 9:00 a.m. EDT. Participants may access the live conference call by dialing 877-407-8031 (domestic) or 201-689-8031 (international). To access the webcast, please visit the AtheroGenics Investor Relations website at http://www.atherogenics.com. Participants may also access a replay of the conference call approximately one hour after the conclusion of the call by dialing 877-660-6853 (domestic) or 201-612-7415 (international). The event will be archived until August 2, 2007.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). AtheroGenics is commencing the ANDES Phase III clinical trial to study its lead anti-inflammatory drug candidate, AGI-1067, in patients with diabetes. In addition, the Company has a clinical-stage development program studying AGI-1096, an oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. For more information about AtheroGenics, please visit http://www.atherogenics.com.

Contact Information

  • CONTACTS:
    AtheroGenics, Inc.
    Donna L. Glasky
    Corporate Communications
    678-336-2517
    Email Contact

    Investor Relations
    Lilian Stern
    Stern Investor Relations, Inc.
    212-362-1200
    Email Contact